Ignite Creation Date:
2024-05-06 @ 3:43 AM
Last Modification Date:
2024-10-26 @ 11:37 AM
Study NCT ID:
NCT02352584
Status:
COMPLETED
Last Update Posted:
2015-10-20
First Post:
2015-01-13
Brief Title:
A Multicenter Double-blind Parallel Phase III Study
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
A Multicenter Randomized Double-blind Active-controlled Parallel Phase III Study to Investigate the EfficacyImmunogenicity and Safety of GC3110AQuadrivalent Influenza Vaccine
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Multicenter Randomized Double-blind Active-controlled Parallel Phase III
Detailed Description:
A Multicenter Randomized Double-blind Active-controlled Parallel Phase III Study to Investigate the EfficacyImmunogenicity and Safety of GC3110AQuadrivalent Influenza Vaccine After Intramuscular Administration in Healthy Subjects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None